Randomized trial of regional plus systemic fluorinated pyrimidine comparedwith systemic fluorinated pyrimidine in treatment of colorectal liver metastases
Tg. Allen-mersh et al., Randomized trial of regional plus systemic fluorinated pyrimidine comparedwith systemic fluorinated pyrimidine in treatment of colorectal liver metastases, EUR J SUR O, 26(5), 2000, pp. 468-473
Aim: We report a prospective randomized study comparing survival, response
and toxicity in colorectal liver metastasis (CLM) patients treated by eithe
r hepatic arterial floxuridine (HAI) plus continuous systemic fluorouracil/
folinic acid or systemic fluorouracil/folinic acid.
Methods: Eighty-four CLM patients received either HAI plus systemic fluorou
racil/folinic acid or systemic fluorouracil/ folinic acid.
Results: Significantly more HAI plus systemic, compared with systemic only,
patients developed WHO grade 3 or 4 diarrhoea (P=0.004), but significant q
uality of life differences were not detected. Liver metastasis partial resp
onse at 4 months after randomization was significantly greater (P=0.003) in
HAI plus systemic (13/29, 45%) compared with systemic only (7/30, 23%) pat
ients. There was no significant difference between groups in the proportion
of patients who died from extrahepatic disease progression, or in survival
.
Conclusion: Combining regional with systemic fluorinated pyrimidines did no
t improve survival compared with systemic fluorinated pyrimidine. (C) 2000
Harcourt Publishers Ltd.